Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 10, 2004, Pages 1125-1131

  Wolfsen, H C ^a   Hemminger, L L ^a   Wallace, M B ^a   Devault, K R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOFRIN;

AGED; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DYSPHAGIA; DYSPLASIA; ENDOSCOPIC THERAPY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STOMACH DISEASE; SYMPTOMATOLOGY; THORAX PAIN;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ATRIAL FIBRILLATION; BARRETT ESOPHAGUS; DIHEMATOPORPHYRIN ETHER; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL PERFORATION; ESOPHAGEAL STENOSIS; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIVITY DISORDERS; TREATMENT OUTCOME;

EID: 10644239275     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02209.x     Document Type: Review

References (24)

1. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
2. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002; 346: 836-42.
3. Prosst RL, Wolfsen HC, Gahlen J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy 2003; 35: 1059-68.
4. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
5. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-40.
6. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 176-86.
7. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8.
8. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132: 612-20.
9. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-7.
10. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc 2002; 77: 1176-81.
11. Ginsberg GG. Endoluminal therapy for Barrett's with high-grade dysplasia and early esophageal adenocarcinoma [editorial]. Clin Gastroenterol Hepatol 2003; 1: 241-5.
12. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7.
13. Pacifico RJ, Wang KK, Wong Kee Song LM, Buttar NS, Lutzke LS. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003; 1: 252-7.
14. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
15. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
16. Sampliner RE. Long-term endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 2003; 98: 1912-3.
17. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 1670-7.
18. DeVault KR, Ward EM, Wolfsen HC, et al. Barrett's esophagus (BE) is common in older patients undergoing screening colonoscopy regardless of gastroesophageal reflux (GER) symptoms (Abstract). Gastrointest Endosc 2004; 59: AB111.
19. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-53.
20. Dulai G, Jensen D, Saad M, Mawas I, Yu J, Fontana L. Simultaneous screening for Barrett's and colorectal cancer (Abstract). Gastrointest Endosc 2004; 59: AB259.
21. Cameron AJ, Souto EO, Smyrk TC. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroenterol 2002; 97: 1375-80.
22. Barr H, Kendall C, Stone N. Photodynamic therapy for esophageal cancer: a useful and realistic option. Technol Cancer Res Treat 2003; 2: 65-76.
23. Overholt BF, Lightdale CJ, Wang KK, Canto M. International multicenter partially binded randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (FOR) for ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE) and results of 24 month follow up. Gastroenterology 2003; 124: A20.
24. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183-8.